peptidylprolyl isomerase A pseudogene 29Genealiases: []
Q-omics provides the consensus-scored PPIAP29 profile across patient tissues and cancer cell-line models. PPIAP29 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, PPIAP29 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PPIAP29 RNA expression shows 14,605 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KIRC, and ACC as cancer lineages where PPIAP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP29 survival associations across molecular data types. PPIAP29 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP29 RNA expression–survival associations across cancer types. High PPIAP29 expression shows unfavorable associations in ACC, UVM, KICH, LUAD and LGG, but favorable associations in THCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for PPIAP29 RNA expression.
This table summarizes PPIAP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP29 shows higher tumor expression in KIRC, LIHC, HNSC, KIRP, BRCA and LUAD. The KIRC box plot shows higher PPIAP29 RNA expression in tumor versus normal tissue (log2 FC = +0.809, t-test p < 0.001).
This table shows molecular features associated with PPIAP29 in patient tissues and cancer cell lines. In patient samples, PPIAP29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
